Werewolf Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Werewolf Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / -57%In 3 years sales changed by -100% while total assets changed by -57%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-2.1×Operating cash was negative last year, while some debt falls due within a year.
Higher than 63% of Healthcare companies in United States.
Cash Cushion Ratio
+39%Cash, after subtracting all debt, equals 39% of its market value (net cash).
Higher than 74% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Werewolf Therapeutics, Inc. made a loss over the last year. Werewolf Therapeutics, Inc. owes $0.33 for every $1 it owns. Werewolf Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossWerewolf Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.01The share price is 3.01 times Werewolf Therapeutics, Inc.'s book value per share, higher than 56% of Healthcare companies in United States.
Market cap
$49 MThe total market value of all of Werewolf Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 74% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$16 MWhat Werewolf Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.34Net worth divided by the number of shares. The share price of $1.01 is 3.0 times this, which is the P/B above.
Return on equity (ROE)
-119.9%Werewolf Therapeutics, Inc. lost 119.9% of its shareholders' money over the last year, lower than 76% of Healthcare companies in United States.
Owes vs Owns
0.33×Werewolf Therapeutics, Inc. owes $0.33 for every $1 it owns (low), lower than 58% of Healthcare companies in United States.
Dividend yield
NoneWerewolf Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossWerewolf Therapeutics, Inc. made a loss in each of the last two years.
Interest cover
Not coveredWerewolf Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashWerewolf Therapeutics, Inc. held $19 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Werewolf Therapeutics, Inc.: $49 M ÷ $16 M (30 Jun 2026) = 3.0.
What is Werewolf Therapeutics, Inc.'s return on equity?
Werewolf Therapeutics, Inc. lost 119.9% of its shareholders' money over the last year, lower than 76% of Healthcare companies in United States.
How much does Werewolf Therapeutics, Inc. owe compared with what it owns?
Werewolf Therapeutics, Inc. owes $0.33 for every $1 it owns (low), lower than 58% of Healthcare companies in United States.
Does Werewolf Therapeutics, Inc. pay a dividend?
No. Werewolf Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.